STAT3 and T-cell large granular lymphocyte leukemia: We extended these results to models of STAT3-driven lymphoproliferative malignancies demonstrating that Hsp90 inhibition effectively reduced both mutant and WT STAT3 phosphorylation and viability of NK cell leukemia/lymphoma cell lines and LGL leukemia patient samples with naturally occurring STAT3 mutations.